Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial

Lancet

Volumn 362, Issue 9397, 2003, Pages 1691-1698

  Olsson, S Bertil ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; BACKACHE; BRONCHITIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISABILITY; DYSPNEA; EDEMA; EMBOLISM; EMBOLISM PREVENTION; EPISTAXIS; HEADACHE; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HEART INFARCTION PREVENTION; HUMAN; INTERNATIONAL STANDARD UNIT; LIVER TOXICITY; MORTALITY; MULTICENTER STUDY; OUTPATIENT DEPARTMENT; PAIN; PRIORITY JOURNAL; PURPURA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE; THORAX PAIN; TREATMENT OUTCOME; VERTIGO;

EID: 0345414673     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14841-6     Document Type: Article

References (30)

1. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 22:1991;983-988.
2. Hart R.G., Benavente O., McBride R., Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 131:1999;492-501.
3. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 156:1996;409-416.
4. Fuster V., Rydén L.E., Asinger R.W., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J. 22:2001;1852-1923.
5. Albers G.W., Dalen J.E., Laupacis A., et al. Antithrombotic therapy in atrial fibrillation. Chest. 119:(suppl):2001;194-206.
6. Hirsh J., Dalen J., Anderson D.R., et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 119:(suppl):2001;8-21.
7. Wells P.S., Holbrook A.M., Crowther N.R., Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 121:1994;676-683.
8. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 333:1995;5-10.
9. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA. 279:1998;1273-1277.
10. Hellemons B.S., Langenberg M., Lodder J., et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 319:1999;958-964.
11. Bungard T.J., Ghali W.A., Teo K.K., McAlister F.A., Tsuyuki R.T. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 160:2000;41-46.
12. Frykman V., Beermann B., Ryden L., Rosenqvist M. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J. 22:2001;1954-1959.
13. Petersen P., Grind M., Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II - a dose-guiding, tolerability, and safety study. J Am Coll Cardiol. 41:2000;1445-1451.
14. Eriksson U.G., Bredberg U., Gislén K., et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol. 59:2003;35-43.
15. Johansson L.C., Frison F., Logren U., Fager G., Gustafsson D., Eriksson U.G. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet. 42:2003;381-392.
16. Sarich T.C., Teng R., Peters G.R., et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet. 42:2003;485-492.
17. Johansson L.C., Andersson M., Fager G., Gustafsson D., Eriksson U.G. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet. 42:2003;475-484.
18. Halperin J.L. and the executive steering committee, on behalf of the SPORTIF III and V study investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J. 146:2000;431-438.
19. Halperin J.L. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J. 146:2003;431-438.
20. van Swieten J.C., Koudstaal P.J., Visser M.C., Schouten H.J., van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 19:1988;604-607.
21. Collin C., Wade D.T., Davies S., Horne V. The Barthel ADL index: a reliability study. Int Disabil Stud. 10:1988;61-63.
22. Ebbutt A.F., Frith L. Practical issues in equivalence trials. Stat Med. 17:1998;1691-1701.
23. Gomberg-Maitland M., Frison L., Halperin J.L. Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality. Am Heart J. 146:2003;398-403.
24. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 84:1991;527-539.
25. Petersen P., Boysen G., Godtfredsen J., Andersen E.D., Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet. 1:1989;175-179.
26. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 323:1990;1505-1511.
27. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 342:1993;1255-1262.
28. Eriksson B.I., Bergqvist D., Kälebo P., et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet. 360:2002;1441-1447.
29. Olsson S.B., Petersen P. Ximelagatran: a long-term oral direct thrombin inhibitor for stroke and systemic embolism prevention in nonvalvular atrial fibrillation patients. Eur Heart J. 23:(suppl):2002;239.
30. Albers G.W., Sherman D.G., Gress D.R., Paulseth J.E., Petersen P. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neurol. 30:1991;511-518.